scholarly journals Effects of aronia berry (poly)phenols on vascular function and gut microbiota: a double-blind randomized controlled trial in adult men

2019 ◽  
Vol 110 (2) ◽  
pp. 316-329 ◽  
Author(s):  
Geoffrey Istas ◽  
Eleanor Wood ◽  
Melanie Le Sayec ◽  
Claudia Rawlings ◽  
Jeeyoung Yoon ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Vascular Function ◽  
Cardiovascular Health ◽  
Controlled Trial ◽  
Healthy Population ◽  
Microbiota Composition ◽  
Double Blind ◽  
Phenolic Metabolites ◽  
Healthy Men ◽  
Gut Microbiota Composition

ABSTRACT Background Aronia melanocarpa is a rich source of (poly)phenols. Previous research has demonstrated that these berries may provide cardiovascular health benefits in high-risk populations. However, very few studies have investigated the effects of daily consumption of dietary achievable amounts of the berries in healthy subjects. Objectives The aim of this study was to investigate the effects of aronia berries on vascular function and gut microbiota composition in a healthy population. Methods A double-blind, placebo-controlled, parallel designed study was conducted in 66 healthy men randomly allocated to consume a (poly)phenol-rich extract (116 mg, 75 g berries), a whole fruit powder (12 mg, 10 g berries), or placebo (maltodextrin) for 12 wk. Flow-mediated dilation (FMD), arterial stiffness, blood pressure, heart rate, and serum biochemistry were assessed. Plasma (poly)phenol metabolites were analyzed by LC-MS. Gut microbiota composition was determined via 16S rRNA sequencing in stool samples. Results Consumption of aronia whole fruit and extract powder for 12 wk led to a significant increase in FMD over control of 0.9% ± 0.4% (95% CI: 0.13%, 1.72%) and 1.2% ± 0.4% (95% CI: 0.36%, 1.97%), respectively. Acute improvements in FMD were also observed 2 h after consumption of aronia extract on day 1 (1.1% ± 0.3%, P = 0.003) and 12 wk later (1.5% ± 0.4%, P = 0.0001). Circulating plasma phenolic metabolites increased upon consumption of the aronia treatments. Although no changes were found in gut microbiota diversity, consumption of aronia extract increased the growth of Anaerostipes (+10.6%, P = 0.01), whereas aronia whole fruit showed significant increases in Bacteroides (+193%, P = 0.01). Correlation analysis identified significant associations between changes in FMD, aronia-derived phenolic metabolites, and specific gut microbial genera. Conclusions In healthy men, consumption of aronia berry (poly)phenols improved endothelial function and modulated gut microbiota composition, indicating that regular aronia consumption has the potential to maintain cardiovascular health in individuals at low risk of cardiovascular disease. This trial was registered at CLINICALTRIALs.gov as NCT03041961.

scholarly journals Metformin induces weight loss associated with gut microbiota alteration in non-diabetic obese women: a randomized double-blind clinical trial

2019 ◽  
Vol 180 (3) ◽  
pp. 165-176 ◽  
Author(s):  
Hanieh-Sadat Ejtahed ◽  
Raul Y Tito ◽  
Seyed-Davar Siadat ◽  
Shirin Hasani-Ranjbar ◽  
Zahra Hoseini-Tavassol ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Gut Microbiota ◽  
Amplicon Sequencing ◽  
Fecal Microbiota ◽  
Pharmacological Therapy ◽  
Microbiota Composition ◽  
Obese Women ◽  
Double Blind ◽  
Baseline Values ◽  
Gut Microbiota Composition

Objective The increasing prevalence of obesity over the past few decades constitutes a global health challenge. Pharmacological therapy is recommended to accompany life-style modification for obesity management. Here, we perform a clinical trial to investigate the effects of metformin on anthropometric indices and gut microbiota composition in non-diabetic, treatment-naive obese women with a low-calorie diet (LCD). Design Randomized double-blind parallel-group clinical trial Methods Forty-six obese women were randomly assigned to the metformin (500 mg/tab) or placebo groups using computer-generated random numbers. Subjects in both groups took two tablets per day for 2 months. Anthropometric measurements and collection of blood and fecal samples were done at the baseline and at the end of the trial. Gut microbiota composition was assessed using 16S rRNA amplicon sequencing. Results Twenty-four and twenty-two subjects were included in the metformin + LCD and placebo + LCD groups, respectively; at the end of trial, 20 and 16 subjects were analyzed. The metformin + LCD and placebo + LCD caused a 4.5 and 2.6% decrease in BMI from the baseline values, respectively (P < 0.01). Insulin concentration decreased in the metformin + LCD group (P = 0.046). The overall fecal microbiota composition and diversity were unaffected in the metformin + LCD group. However, a significant specific increase in Escherichia/Shigella abundance was observed after metformin + LCD intervention (P = 0.026). Fecal acetate concentration, but not producers, was significantly higher in the placebo + LCD group, adjusted for baseline values and BMI (P = 0.002). Conclusions Despite the weight reduction after metformin intake, the overall fecal microbiota composition remained largely unchanged in obese women, with exception of changes in specific proteobacterial groups.

scholarly journals Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults

2020 ◽  
pp. 1-10
Author(s):  
R.E. Trotter ◽  
A.R. Vazquez ◽  
D.S. Grubb ◽  
K.E. Freedman ◽  
L.E. Grabos ◽  
...  
Keyword(s):  
Bacillus Subtilis ◽  
Endothelial Function ◽  
Vascular Function ◽  
Cardiovascular Health ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Subtilis Strain ◽  
Healthy Population ◽  
Healthy Human ◽  
Double Blind

Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide. By 2030 it is anticipated that CVD will claim the lives of more than 24 million people. Throughout the last decade, researchers have investigated the role of the gut microbiota in the development of CVD. Evidence exists for a positive correlation between Bifidobacterium and vascular function, glucose tolerance, and reduced systemic inflammation. Another probiotic species, Bacillus subtilis, has also been found to reduce cholesterol levels in human and animal models. In light of these data, we examined various measures of cardiovascular health after consumption of Bifidobacterium animalis subsp. lactis strain BL04, with and without a cocktail of Escherichia coli-targeting bacteriophages (marketed as PreforPro), Bacillus subtilis strain DE111 or a maltodextrin-based placebo in a healthy human population. In a randomised, double-blind, placebo-controlled 4-week intervention conducted in individuals 18 to 65 years of age with a body mass index of 20 to 34.9, we saw no significant changes in measured CVD parameters among individuals consuming B. lactis with or without bacteriophages. However, B. subtilis supplementation resulted in a significant reduction in total cholesterol relative to baseline measures (-8 mg/dl; P=0.04, confidence interval (CI): -13.40, -0.19), as well as non-high-density lipoprotein-cholesterol (-11 mg/dl; P=0.01, CI: -12.43, -2.07). In addition we observed trending improvements in endothelial function (P=0.05, CI: -0.003, 0.370) and in low-density lipoprotein-cholesterol (P=0.06, CI:-12.29, 0.2864). Strikingly, these effects were seen in a largely healthy population. These data suggest that B. subtilis supplementation may be beneficial for improving risk factors associated with CVD. Further studies in populations of older adults or those with dyslipidaemia and endothelial dysfunction is warranted.

Effect of multispecies probiotic on gut microbiota composition in individuals with intestinal constipation: A double-blind, placebo-controlled randomized trial

Nutrition ◽  
2020 ◽  
Vol 78 ◽  
pp. 110890 ◽  
Author(s):  
Patrícia Borges Botelho ◽  
Marcus Vinícius Rodrigues Ferreira ◽  
Ananda de Mesquita Araújo ◽  
Marcela Moraes Mendes ◽  
Eduardo Yoshio Nakano
Keyword(s):  
Gut Microbiota ◽  
Randomized Trial ◽  
Microbiota Composition ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Gut Microbiota Composition

scholarly journals Comprehensive analysis of gut microbiota of a healthy population and covariates affecting microbial variation in two large Japanese cohorts

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jonguk Park ◽  
Kumiko Kato ◽  
Haruka Murakami ◽  
Koji Hosomi ◽  
Kumpei Tanisawa ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Large Scale ◽  
Univariate Analysis ◽  
Comprehensive Analysis ◽  
Dietary Habit ◽  
Healthy Population ◽  
Microbiota Composition ◽  
Microbial Composition ◽  
Factors Associated ◽  
Gut Microbiota Composition

Abstract Background Inter-individual variations in gut microbiota composition are observed even among healthy populations. The gut microbiota may exhibit a unique composition depending on the country of origin and race of individuals. To comprehensively understand the link between healthy gut microbiota and host state, it is beneficial to conduct large-scale cohort studies. The aim of the present study was to elucidate the integrated and non-redundant factors associated with gut microbiota composition within the Japanese population by 16S rRNA sequencing of fecal samples and questionnaire-based covariate analysis. Results A total of 1596 healthy Japanese individuals participated in this study via two independent cohorts, NIBIOHN cohort (n = 954) and MORINAGA cohort (n = 642). Gut microbiota composition was described and the interaction of these microorganisms with metadata parameters such as anthropometric measurements, bowel habits, medical history, and lifestyle were obtained. Thirteen genera, including Alistipes, Anaerostipes, Bacteroides, Bifidobacterium, Blautia, Eubacterium halli group, Faecalibacterium, Fusicatenibacter, Lachnoclostridium, Parabacteroides, Prevotella_9, Roseburia, and Subdoligranulum were predominant among the two cohorts. On the basis of univariate analysis for overall microbiome variation, 18 matching variables exhibited significant association in both cohorts. A stepwise redundancy analysis revealed that there were four common covariates, Bristol Stool Scale (BSS) scores, gender, age, and defecation frequency, displaying non-redundant association with gut microbial variance. Conclusions We conducted a comprehensive analysis of gut microbiota in healthy Japanese individuals, based on two independent cohorts, and obtained reliable evidence that questionnaire-based covariates such as frequency of bowel movement and specific dietary habit affects the microbial composition of the gut. To our knowledge, this was the first study to investigate integrated and non-redundant factors associated with gut microbiota among Japanese populations.

scholarly journals Gut Microbiota Composition and Fecal Metabolic Profiling in Patients With Diabetic Retinopathy

2021 ◽  
Vol 9 ◽  
Author(s):  
Zixi Zhou ◽  
Zheng Zheng ◽  
Xiaojing Xiong ◽  
Xu Chen ◽  
Jingying Peng ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Gut Microbiota ◽  
Metabolic Phenotype ◽  
Healthy Population ◽  
Healthy Controls ◽  
Microbiota Composition ◽  
Gut Microbiota Composition

Recent evidence suggests there is a link between metabolic diseases and gut microbiota. To investigate the gut microbiota composition and fecal metabolic phenotype in diabetic retinopathy (DR) patients. DNA was extracted from 50 fecal samples (21 individuals with type 2 diabetes mellitus-associated retinopathy (DR), 14 with type 2 diabetes mellitus but without retinopathy (DM) and 15 sex- and age-matched healthy controls) and then sequenced by high-throughput 16S rDNA analysis. Liquid chromatography mass spectrometry (LC-MS)-based metabolomics was simultaneously performed on the samples. A significant difference in the gut microbiota composition was observed between the DR and healthy groups and between the DR and DM groups. At the genus level, Faecalibacterium, Roseburia, Lachnospira and Romboutsia were enriched in DR patients compared to healthy individuals, while Akkermansia was depleted. Compared to those in the DM patient group, five genera, including Prevotella, were enriched, and Bacillus, Veillonella, and Pantoea were depleted in DR patients. Fecal metabolites in DR patients significantly differed from those in the healthy population and DM patients. The levels of carnosine, succinate, nicotinic acid and niacinamide were significantly lower in DR patients than in healthy controls. Compared to those in DM patients, nine metabolites were enriched, and six were depleted in DR patients. KEGG annotation revealed 17 pathways with differentially abundant metabolites between DR patients and healthy controls, and only two pathways with differentially abundant metabolites were identified between DR and DM patients, namely, the arginine-proline and α-linolenic acid metabolic pathways. In a correlation analysis, armillaramide was found to be negatively associated with Prevotella and Subdoligranulum and positively associated with Bacillus. Traumatic acid was negatively correlated with Bacillus. Our study identified differential gut microbiota compositions and characteristic fecal metabolic phenotypes in DR patients compared with those in the healthy population and DM patients. Additionally, the gut microbiota composition and fecal metabolic phenotype were relevant. We speculated that the gut microbiota in DR patients may cause alterations in fecal metabolites, which may contribute to disease progression, providing a new direction for understanding DR.

scholarly journals Inter-individual Variability in Gut Microbiota Composition Is Associated With Changes in the Fecal Metabolome of Individuals Consuming a Military Ration Diet

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 1164-1164
Author(s):  
J Philip Karl ◽  
Nicholes Armstrong ◽  
Patrick Radcliffe ◽  
Holly McClung
Keyword(s):  
Gut Microbiota ◽  
Controlled Trial ◽  
Gastrointestinal Symptoms ◽  
Individual Variability ◽  
Error Rates ◽  
Microbiota Composition ◽  
Principal Coordinates Analysis ◽  
Medicine Research ◽  
Principal Coordinates ◽  
Gut Microbiota Composition

Abstract Objectives The fecal metabolome provides a functional readout of interactions between host, diet and the gut microbiota that may help identify gut microbiota-derived compounds associated with health outcomes. This study aimed to determine associations between inter-individual variability in gut microbiota composition, diet-induced changes in the fecal metabolome and gastrointestinal symptoms in adults consuming a diet consisting solely of military rations. Methods Secondary analysis of a randomized-controlled trial in which 54 healthy adults (32 ± 14 yr, BMI 26 ± 3 kg/m2) were randomly assigned to consume their usual diet (Control) or a provided diet of Meal, Ready-to-Eat military rations (MRE) for 3wk. Fecal microbiota composition was measured by 16S rRNA sequencing and the fecal metabolome by untargeted UPLC-MS/MS at baseline and post-intervention. Self-reported gastrointestinal symptoms were measured weekly using the Irritable Bowel Severity Scoring System (IBSSS). Results Principal coordinates analysis of baseline gut microbiota composition separated MRE participants into two clusters determined primarily by ratio of Bacteroides to Prevotella (HIGH (n = 17) or LOW (n = 10)). Random Forest classification of changes in the fecal metabolome within Control, HIGH, and LOW produced error rates of 7%, 18% and 100%, respectively, suggesting a more discriminant metabolome response in HIGH than LOW. Between-group differences in 153 metabolites were detected by ANOVA (FDR &lt;0.20). Among those, 39 identified and 20 unidentified metabolites demonstrated an association with the gut microbiota (HIGH vs. LOW, P &lt; 0.05). Compounds within xenobiotic, peptide/amino acid, and lipid metabolism pathways comprised 29 of the microbiota-associated metabolites. Changes in microbiota-associated metabolites were not correlated with changes in IBSSS scores. Conclusions Changes in the fecal metabolome of individuals consuming a short-term military ration diet are associated with inter-individual variability in gut microbiota composition, but changes in microbiota-associated fecal metabolites do not appear to impact gastrointestinal symptoms. Funding Sources Military Operational Medicine Research Program. Disclaimer Authors’ views do not reflect official DoD or Army policy.

Sign in / Sign up

Export Citation Format

Share Document